CRIS Current Research Information System

COSMI, BENILDE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.263
EU - Europa 3.340
AS - Asia 1.217
AF - Africa 132
SA - Sud America 13
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.969
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.260
GB - Regno Unito 1.154
DE - Germania 554
CN - Cina 548
IT - Italia 377
SE - Svezia 361
VN - Vietnam 336
IN - India 265
UA - Ucraina 207
IE - Irlanda 168
RU - Federazione Russa 150
FR - Francia 148
ZA - Sudafrica 93
EE - Estonia 91
CH - Svizzera 23
BE - Belgio 19
CZ - Repubblica Ceca 19
GR - Grecia 16
JO - Giordania 16
SC - Seychelles 16
FI - Finlandia 15
TG - Togo 14
JP - Giappone 12
BG - Bulgaria 7
CI - Costa d'Avorio 7
HK - Hong Kong 6
LB - Libano 6
RO - Romania 6
SG - Singapore 6
CL - Cile 5
NL - Olanda 5
TR - Turchia 5
BR - Brasile 4
HR - Croazia 4
TW - Taiwan 4
AT - Austria 3
CA - Canada 3
DK - Danimarca 3
ES - Italia 3
ID - Indonesia 3
PL - Polonia 3
UZ - Uzbekistan 3
AR - Argentina 2
AU - Australia 2
IL - Israele 2
KR - Corea 2
NO - Norvegia 2
PE - Perù 2
SA - Arabia Saudita 2
EU - Europa 1
HU - Ungheria 1
MA - Marocco 1
MC - Monaco 1
MY - Malesia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
Totale 9.969
Salva come PNG Salva come JPEG
Città #
Southend 1.055
Fairfield 942
Ashburn 447
Woodbridge 403
Chandler 393
Wilmington 379
Seattle 376
Houston 366
Cambridge 324
Princeton 309
Dong Ket 267
Ann Arbor 206
Dublin 165
Jacksonville 122
Westminster 114
Nanjing 112
Padova 99
Berlin 93
San Diego 63
Shenyang 60
Turin 57
Jinan 54
Saint Petersburg 52
Bologna 47
Hebei 40
Dearborn 39
Redmond 37
Changsha 34
Nanchang 32
Des Moines 27
Beijing 26
Mülheim 25
Milan 21
Falls Church 20
Boardman 19
Brussels 19
Tianjin 19
Bühl 18
Hangzhou 18
Jiaxing 18
Norwalk 17
Olalla 17
Zhengzhou 17
Amman 16
Bern 16
Mahé 15
Lomé 14
Taiyuan 14
Bremen 13
Chicago 13
Haikou 13
Helsinki 13
Lanzhou 12
London 12
Fuzhou 11
San Venanzo 11
Taizhou 11
Tokyo 11
Medford 10
Redwood City 9
Washington 8
Abidjan 7
Los Angeles 7
Moscow 7
New York 7
Ningbo 7
Sofia 7
Verona 7
Cesena 6
Kunming 6
Paris 6
Frankfurt Am Main 5
Guangzhou 5
Rome 5
Kiev 4
Parma 4
Piacenza 4
Taipei 4
Torino 4
Athens 3
Boydton 3
Costa Mesa 3
Esslingen am Neckar 3
Hefei 3
Lausanne 3
Listowel 3
Luzzara 3
Madrid 3
San Jose 3
Scottsdale 3
Sleman 3
São Paulo 3
Tappahannock 3
Buffalo 2
Castenaso 2
Cernusco sul Naviglio 2
Chengdu 2
Chongqing 2
Copenhagen 2
Den Haag 2
Totale 7.348
Salva come PNG Salva come JPEG
Nome #
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). 163
Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. 157
Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. 139
Age and gender specific cut-off values to improve the performance of D: -dimer assays to predict the risk of venous thromboembolism recurrence. 128
Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. 127
Diagnostic Accuracy of a New d -Dimer Assay (Sclavo Auto d -Dimer) for Exclusion of Deep Vein Thrombosis in Symptomatic Outpatients 126
D-Dimer testing for predictive recurrence risk in venous thromboembolism: looking for a useful threshold: reply to a rebuttal. 108
D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 107
High plasma levels of factor VIII and risk of recurrence of venous thromboembolism 107
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. 106
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study 105
Anticoagulant therapy for symptomatic calf deep vein thrombosis 105
Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register 104
Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. 103
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study 101
Diagnosis of deep vein thrombosis. 100
D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis. 100
D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis 100
Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH 99
Review: recombinant factor VIIa does not differ from placebo for prevention or treatment of bleeding in patients without hemophilia 98
Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. 97
Evaluation of a chemiluminescent immunoassay, the HemosIL AcuStar D-Dimer, in outpatients with clinically suspected deep venous thrombosis 97
External validation of the DASH prediction rule: a retrospective cohort study 97
Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. 95
D-dimer, FVIII and thrombotic burden in the acute phase of deep vein thrombosis in relation to the risk of post-thrombotic syndrome 94
Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis. 94
Current management strategies and long-term clinical outcomes of upper extremity venous thrombosis 94
Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 93
An update on the pharmaceutical management of thrombosis 93
Inherited and acquired thrombophilic alterations in patients with superficial vein thrombosis of lower limbs 91
D-dimer, oral anticoagulation, and venous thromboembolism recurrence 91
Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients 91
D-dimer use for deep venous thrombosis exclusion in elderly patients: a comparative analysis of three different approaches to establish cut-off values for an assay with results expressed in D-dimer units 91
The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers--two independent studies. 90
Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 90
Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication 90
ACP Journal Club. Review: Low-molecular-weight heparin reduces risk for venous thromboembolism in adults with leg immobilization. 89
D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 88
Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. 86
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms 86
The incidence of heparin-induced thrombocytopenia in patients treated with low molecular weight heparin for superficial vein thrombosis 86
D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the Prolong extension study. 86
Thrombin generation and intracranial atherosclerotic disease in patients with a transient ischaemic attack 85
Malattia tromboembolica polmonare 84
Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. 84
Value of D-dimer testing to decide duration of anticoagulation after deep vein thrombosis: yes. 84
Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis 83
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations 82
Is there a role for oral anticoagulant therapy in patients with peripheral arterial disease? 82
Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. 82
Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. 81
Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). 81
Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: A prospective multicenter study 81
The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: A prospective cohort study (the PROLONG PLUS study). 80
null 80
Risks factors for highly unstable response to oral anticoagulation: a case-control study. 80
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. 80
Predicting the risk of recurrence of venous thromboembolism. 79
Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. 79
Measurement of factor XIII (FXIII) activity by an automatic ammonia release assay using iodoacetamide blank-procedure: no more overestimation in the low activity range and better detection of severe FXIII deficiencies 79
Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor. 78
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 78
Heparin-induced thrombocytopenia: new insights into the immune response 78
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. 78
Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. 77
Whole-Arm Ultrasound to Rule Out Suspected Upper-Extremity Deep Venous Thrombosis in Outpatients 77
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. 77
Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therap 77
Whole-Arm Ultrasound for Suspected Upper-Extremity Deep Venous Thrombosis in Outpatients Reply 76
Ultrasound Characteristics of Calf Deep Vein Thrombosis and Residual Vein Obstruction After Low Molecular Weight Heparin Treatment 76
The influence of VKORC1 3730 G > A polymorphism on warfarin dose: reply. 75
Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans 75
ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. 73
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 73
The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis 73
Duration of anticoagulation after isolated pulmonary embolism 72
Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum) 71
Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia 70
Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, D-Dimer Testing, and Ultrasonography for Suspected Upper Extremity Deep Venous Thrombosis A Prospective Management Study 70
Management of idiopathic venous thromboembolism 70
Monitoring patients with the lupus anticoagulant while treated with vitamin K antagonists: communication from the SSC of the ISTH 70
Emerging drugs for venous thromboembolism. 70
The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs 69
Current management of heparin-induced thrombocytopenia 69
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 69
Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of a portable prothrombin time monitor (COAGUCHECK) 69
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study: reply 68
D-dimer testing to determine the duration of anticoagulation therapy. 68
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree? 68
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants 67
Endothelial activation in patients with superficial vein thrombosis (SVT) of the lower limbs 67
Management of superficial vein thrombosis 66
The current management strategies and clinical outcome of upper extremity deep vein thrombosis 65
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 65
Extended treatment for venous thromboembolism: how long is long enough? 64
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis A patient-level meta-analysis 63
D-dimer testing to determine the duration of anticoagulant therapy. 63
Is there a role for intervention radiology for the treatment of lower limb deep vein thrombosis in the era of direct oral anticoagulants? A comprehensive review 62
THE ADDITIVE EFFECT OF LOW-MOLECULAR-WEIGHT HEPARINS ON THROMBIN INHIBITION BY DERMATAN SULFATE 62
Old and new heparins. 58
Totale 8.574
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.980
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.980
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019166 0 0 0 0 0 0 0 0 0 0 61 105
2019/20203.274 432 81 28 169 335 374 401 442 508 220 143 141
2020/20211.612 339 132 45 68 19 50 40 111 251 81 74 402
2021/20222.051 205 95 177 116 246 111 63 207 87 97 289 358
2022/20232.016 261 281 117 275 111 162 59 116 283 93 172 86
2023/2024372 36 97 44 30 28 20 20 35 19 41 2 0
Totale 10.324